Last reviewed · How we verify

NCT03511885: EUROASPIRE

EUROASPIRE V Survey on Cardiovascular Disease Prevention and Diabetes

Completed Last updated 15 August 2019
What this trial tests

trial testing There is no intervention in Cardiovascular Diseases in 1,736 participants. Completed in 28 December 2018.

Timeline
23 August 2016
Primary endpoint
28 December 2018
28 December 2018

Quick facts

Lead sponsorImperial College London
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,736
Start date23 August 2016
Primary completion28 December 2018
Estimated completion28 December 2018
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Imperial College London

Who can join

Adults 18 to 80, any sex, with Cardiovascular Diseases or Coronary Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

EUROASPIRE is a multicentre European study in coronary patients and individuals at high risk of developing cardiovascular disease (CVD), describing their management through lifestyle and use of drug therapies and providing an objective assessment of clinical implementation of current scientific knowledge. Four EUROASPIRE surveys have been carried out by the European Society of Cardiology so far: EUROASPIRE I in 1995-1997 in nine countries, EUROASPIRE II in 1999- 2000 in 15 countries, EUROASPIRE III in 2006-2009 in 22 countries and EUROASPIRE IV in 2012-2015 in 26 countries. The results showed a wide gap between the recommendations and clinical practice with many patients not achieving the lifestyle and medical risk factors goals for CVD prevention. The fifth EUROASPIRE survey is planned for 2016-2018 to determine in hospital coronary patients and apparently healthy individuals in primary care at high risk of developing cardiovascular disease whether the European and national guidelines on cardiovascular disease prevention have been followed and if the practice of preventive cardiology in EUROASPIRE IV has improved by comparison with those centres which took part in EUROASPIRE I, II, III and IV. This survey will also incorporate an assessment of dysglycaemia and kidney function in all patients. The main outcome measures will be the proportions of coronary and high cardiovascular risk patients achieving the lifestyle, risk factor and therapeutic targets for cardiovascular disease prevention. The data collection will be based on a review of patient medical records and a patient interview and examination at least 6 months and at most 3 years after recruiting event. All countries which participated in the first three surveys will be invited to take part in EUROASPIRE V. This fifth survey will give a unique picture of preventive action by cardiologists and primary care physicians looking after patients with coronary disease and individuals at high CVD risk.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Secondary prevention in diabetic and nondiabetic coronary heart disease patients: Insights from the German subset of the hospital arm of the EUROASPIRE IV and V surveys.
    Ungethüm K, Wiedmann S, Wagner M, Leyh R, et al · · 2023 · cited 3× · PMID 36166067 · DOI 10.1007/s00392-022-02093-0

Verify or expand the search:

Other trials of There is no intervention

Trials testing the same drug.

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other Imperial College London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03511885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing